A simple, rapid, and cost-effective UV-Vis spectrophotometric method was successfully developed and validated for the estimation of apixaban in bulk and oral dosage forms.
New spectrophotometric assay for apixaban in formulations now available; leaves open clinical validation and therapeutic monitoring use.
A simple, rapid, cost effective and extractive UV-Vis spectrophotometric method has been developed for the determination of Apixaban (AP) in bulk drug and pharmaceutical formulation. It was based on UV-Vis spectrophotometric measurements in which the drug reacts chromogenic reagent (N-(1-napthyl) ethylene diamine dihydrochloride solution) in acidic medium and give stable pale yellow colored complex which exhibits absorption maximum at 680 nm. Beer’s law was obeyed in the concentration range of 5 - 50 μg /ml. This method was tested and validated for various parameters according to ICH guidelines. The proposed method was successfully applied for the determination of AP in oral formulation. The results demonstrated that the procedure is accurate, precise and reproducible (relative standard deviation < 2 %). As it is simple, cheap and less time consuming, it can be suitably applied for the estimation of LA in dosage forms in quality control labs.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: